Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2010 1
2012 2
2014 1
2015 2
2016 3
2017 7
2018 8
2019 7
2020 13
2021 16
2022 6
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Results by year

Filters applied: . Clear all
Page 1
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.
Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenkov Y, Herbst RS; ADAURA Investigators. Wu YL, et al. N Engl J Med. 2020 Oct 29;383(18):1711-1723. doi: 10.1056/NEJMoa2027071. Epub 2020 Sep 19. N Engl J Med. 2020. PMID: 32955177 Clinical Trial.
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Shire N, Jiang H, Goldman JW; CASPIAN investigators. Paz-Ares L, et al. Lancet. 2019 Nov 23;394(10212):1929-1939. doi: 10.1016/S0140-6736(19)32222-6. Epub 2019 Oct 4. Lancet. 2019. PMID: 31590988 Clinical Trial.
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.
Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohé C, Wang J, Goldman JW, Lu S, Su WC, de Marinis F, Shepherd FA, Lee KH, Le NT, Dechaphunkul A, Kowalski D, Poole L, Bolanos A, Rukazenkov Y, Wu YL; ADAURA Investigators. Tsuboi M, et al. N Engl J Med. 2023 Jul 13;389(2):137-147. doi: 10.1056/NEJMoa2304594. Epub 2023 Jun 4. N Engl J Med. 2023. PMID: 37272535 Clinical Trial.
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, Mansfield AS, Popat S, Jahan T, Antonia S, Oulkhouir Y, Bautista Y, Cornelissen R, Greillier L, Grossi F, Kowalski D, Rodríguez-Cid J, Aanur P, Oukessou A, Baudelet C, Zalcman G. Baas P, et al. Among authors: cornelissen r. Lancet. 2021 Jan 30;397(10272):375-386. doi: 10.1016/S0140-6736(20)32714-8. Epub 2021 Jan 21. Lancet. 2021. PMID: 33485464 Clinical Trial.
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Garassino MC, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Każarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Thiyagarajah P, Jiang H, Paz-Ares L; CASPIAN investigators. Goldman JW, et al. Lancet Oncol. 2021 Jan;22(1):51-65. doi: 10.1016/S1470-2045(20)30539-8. Epub 2020 Dec 4. Lancet Oncol. 2021. PMID: 33285097 Clinical Trial.
Lung Cancer in the Netherlands.
Hendriks LEL, Dingemans AC, De Ruysscher DKM, Aarts MJ, Barberio L, Cornelissen R, Hartemink KJ, van den Heuvel M, Schuuring E, Smit HJM, van der Wekken AJ, Smit EF. Hendriks LEL, et al. Among authors: cornelissen r. J Thorac Oncol. 2021 Mar;16(3):355-365. doi: 10.1016/j.jtho.2020.10.012. J Thorac Oncol. 2021. PMID: 33641718 Free article. No abstract available.
Multi-source data approach for personalized outcome prediction in lung cancer screening: update from the NELSON trial.
Sidorenkov G, Stadhouders R, Jacobs C, Mohamed Hoesein FAA, Gietema HA, Nackaerts K, Saghir Z, Heuvelmans MA, Donker HC, Aerts JG, Vermeulen R, Uitterlinden A, Lenters V, van Rooij J, Schaefer-Prokop C, Groen HJM, de Jong PA, Cornelissen R, Prokop M, de Bock GH, Vliegenthart R. Sidorenkov G, et al. Among authors: cornelissen r. Eur J Epidemiol. 2023 Apr;38(4):445-454. doi: 10.1007/s10654-023-00975-9. Epub 2023 Mar 21. Eur J Epidemiol. 2023. PMID: 36943671 Free PMC article. Clinical Trial.
Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4).
Cornelissen R, Prelaj A, Sun S, Baik C, Wollner M, Haura EB, Mamdani H, Riess JW, Cappuzzo F, Garassino MC, Heymach JV, Socinski MA, Leu SY, Bhat G, Lebel F, Le X; ZENITH20-4 Investigators. Cornelissen R, et al. J Thorac Oncol. 2023 Aug;18(8):1031-1041. doi: 10.1016/j.jtho.2023.03.016. Epub 2023 Mar 21. J Thorac Oncol. 2023. PMID: 36958688 Clinical Trial.
Checkpoint Blockade in Lung Cancer and Mesothelioma.
Lievense LA, Sterman DH, Cornelissen R, Aerts JG. Lievense LA, et al. Among authors: cornelissen r. Am J Respir Crit Care Med. 2017 Aug 1;196(3):274-282. doi: 10.1164/rccm.201608-1755CI. Am J Respir Crit Care Med. 2017. PMID: 28252315 Review.
63 results